SANTA ROSA, Calif. – February 27, 2017 – Claret Medical® today announced...
Hank is a General Partner of Lightstone Ventures. He focuses on medical device investments out of the firm’s Menlo Park, CA office. Hank also serves as a General Partner at Morgenthaler Ventures which he joined in 2007 after more than 25 years in the life science industry. Prior to becoming a venture capitalist, he co-founded eight medical device companies. He has served as a director for nine companies that have had successful exits with a combined value in excess of $3 billion.
In August 2015, Medtronic announced plans to acquire Twelve, Inc. for $408 million and milestone payments of $50 million. In May 2014, Cardinal Health completed the acquisition of Access Closure for $320 million. In June 2014, Ulthera, Inc. acquired Cabochon Aesthetics in cash and milestone payments. Hank served as a board member of the three companies.
In 2011, Medtronic completed the acquisition of Ardian for $800 million. Hank was a founder, helped incubate Ardian while at The Foundry, and served as a Director of the company. In 2010, Hank was a board member during the $785 million acquisition of Acclarent by Johnson & Johnson.
Hank led the Lightstone investment and serves on the board of Earlens and Claret. He also serves on the boards of Morgenthaler portfolio companies – Holaira, Kona Medical, Miramar Labs and Setpoint Medical.
From 2000-2007 Hank served as Vice-Chairman of The Foundry where he co-founded Ardian, Cabochon Aesthetics, ForSight Labs, ForSight Vision2, Miramar Labs, and Transcend. From 1993 to 2000, he served as President and CEO of Perclose, Inc., where he led the company to $100 million in sales, a successful IPO and a $680 million acquisition in 1999 by Abbott Laboratories. He was Chairman of Embolic Protection, where he helped negotiate the acquisition of the company in 2001 by Boston Scientific. He also served as a Director at TransVascular until Medtronic acquired the company in 2003. Previously, Hank worked at Eli Lilly for 12 years in various management positions.
B.S. in Finance from University of Missouri – Columbia
02.27.17FDA Advisory Committee Strongly Supports Granting De Novo Application For The First Cerebral Protection System For Transcatheter Aortic Valve Replacement (TAVR)
11.28.16Hank Plain long-time backer of Institute
11.07.16Miramar Labs, Inc.® Receives U.S. FDA 510(k) Clearance for Reduction of Odor